Angelo Martignetti

1.3k total citations
30 papers, 645 citations indexed

About

Angelo Martignetti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Angelo Martignetti has authored 30 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Angelo Martignetti's work include Renal cell carcinoma treatment (6 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Treatment and Pharmacology (5 papers). Angelo Martignetti is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Treatment and Pharmacology (5 papers). Angelo Martignetti collaborates with scholars based in Italy, United States and Spain. Angelo Martignetti's co-authors include Liliana Montella, Giovannella Palmieri, Sergio Crispino, Michele Caraglia, Secondo Lastoria, Dolores Di Vizio, A. Ciccarelli, Vincenzo Nuzzo, Giovanni Lupoli and Francesco Fonderico and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Angelo Martignetti

29 papers receiving 624 citations

Peers

Angelo Martignetti

ONCOL

PRM

EDM

NEURO

Fernando Franco Spain

Eric Lipp United States

Shin-ichi Yamashita Japan

Jack Dalton United States

Lise Tremblay Canada

Ryuta Tanimoto Japan

Jason Zhu United States

Yukie Takimoto Japan

Edwin Alvarez United States

S. Garcia France

Fernando Franco Spain

Angelo Martignetti

305 ×1.0

ONCOL

211 ×1.3

PRM

215 ×1.4

52 ×0.5

EDM

80 ×0.8

NEURO

Citations per year, relative to Angelo Martignetti Angelo Martignetti (= 1×) peers Fernando Franco

Countries citing papers authored by Angelo Martignetti

Since Specialization

Citations

This map shows the geographic impact of Angelo Martignetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo Martignetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo Martignetti more than expected).

Fields of papers citing papers by Angelo Martignetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo Martignetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo Martignetti. The network helps show where Angelo Martignetti may publish in the future.

Co-authorship network of co-authors of Angelo Martignetti

This figure shows the co-authorship network connecting the top 25 collaborators of Angelo Martignetti. A scholar is included among the top collaborators of Angelo Martignetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo Martignetti. Angelo Martignetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Santoni, Matteo, Francesco Massari, Marc Matrana, et al.. (2022). Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer. 172. 191–198. 15 indexed citations

Santoni, Matteo, Francesco Massari, Sergio Bracarda, et al.. (2022). Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. European Urology Focus. 8(6). 1696–1702. 22 indexed citations

Santoni, Matteo, Gaetano Aurilio, Francesco Massari, et al.. (2022). Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clinical Genitourinary Cancer. 20(3). 285–295. 6 indexed citations

Moretto, Roberto, Daniele Rossini, Iolanda Capone, et al.. (2021). Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clinical Colorectal Cancer. 20(4). 314–317. 12 indexed citations

Santoni, Matteo, Francesco Massari, Sergio Bracarda, et al.. (2021). Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. Diagnostics. 11(1). 138–138. 11 indexed citations

Rossi, Lorenzo, Chiara Biagioni, Amelia McCartney, et al.. (2019). Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Research. 21(1). 71–71. 20 indexed citations

Marmorino, Federica, Lisa Salvatore, C. Barbara, et al.. (2017). Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer. 116(3). 318–323. 33 indexed citations

Vivaldi, Caterina, P Buccianti, Gianna Musettini, et al.. (2016). TRUST: Phase II trial of induction chemotherapy (CT) with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC). Annals of Oncology. 27. vi170–vi170.

Rossi, David, Donatella Sarti, Lara Malerba, et al.. (2016). Secondary Bone Marrow Malignancies after Adjuvant Chemotherapy for Breast Cancer: A Report of 2 Cases and a Review of the Literature. Tumori Journal. 102(2_suppl). S29–S31. 1 indexed citations

10.

Bracarda, Sergio, Roberto Iacovelli, Mimma Rizzo, et al.. (2014). Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. Journal of Clinical Oncology. 32(4_suppl). 471–471. 10 indexed citations

11.

Martignetti, Angelo, et al.. (2010). Art therapy with cancer patients during chemotherapy sessions: An analysis of the patients' perception of helpfulness. Palliative & Supportive Care. 8(1). 41–48. 51 indexed citations

12.

Torino, Francesco, Stefano Cascinu, Fortunato Ciardiello, et al.. (2008). A phase II study of neoadjuvant antiangiogenic therapy combined with capecitabine (C) and radiotherapy (RT) in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology. 26(15_suppl). 15113–15113. 1 indexed citations

13.

Zampino, Maria Giulia, Elena Magni, Cristian Massacesi, et al.. (2007). First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first‐line treatment for metastatic colorectal cancer. Cancer. 110(4). 752–758. 26 indexed citations

14.

Zampino, Maria Giulia, Elena Magni, Laura Zorzino, et al.. (2007). Epidermal growth factor receptor (EGFR) serum level may predict response in patients with advanced colorectal cancer (ACC) treated with gefitinib. Journal of Clinical Oncology. 25(18_suppl). 4119–4119. 1 indexed citations

15.

Minenkova, Olga, Andrea Pucci, Emiliano Pavoni, et al.. (2003). Identification of tumor‐associated antigens by screening phage‐displayed human cDNA libraries with sera from tumor patients. International Journal of Cancer. 106(4). 534–544. 70 indexed citations

16.

Palmieri, Giovannella, et al.. (2002). Ultra-Low-Dose Interleukin-2 in Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology. 25(3). 224–226. 27 indexed citations

17.

Palmieri, Giovannella, Liliana Montella, Angelo Martignetti, et al.. (2002). Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. 94(5). 1414–1420. 73 indexed citations

18.

Vitale, Giovanni, Francesco Fonderico, Angelo Martignetti, et al.. (2001). Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. British Journal of Cancer. 84(12). 1586–1590. 80 indexed citations

19.

Palmieri, Giovannella, Liliana Montella, Angelo Martignetti, & Antonio Bianco. (2000). Interferon alpha-2b at low doses as long-term antiangiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report.. Oncology Reports. 7(1). 145–9. 30 indexed citations

20.

Tagliaferri, Pierosandro, Carmen Barile, Michele Caraglia, et al.. (1998). Daily Low-Dose Subcutaneous Recombinant Interleukin-2 by Alternate Weekly Administration. American Journal of Clinical Oncology. 21(1). 48–53. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact